Immunovant, Inc. - Common Stock — 재무제표 (NASDAQ:IMVT) | MetaTrader

전체 차트 열기 Full chart

Financials

개요 성명 통계

총자산 412.49 M515.56 M405.84 M666.37 M776.22 M957.01 M 총 부채 21.01 M45.74 M43.34 M48.61 M68.78 M104.42 M 자본금 총액 391.48 M469.82 M362.49 M617.76 M707.45 M852.59 M 총 부채 및 주주자본 412.49 M515.56 M405.84 M666.37 M776.22 M957.01 M 총부채 —————— 순부채 ——————

뉴스

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT)

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV)

These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Immunovant (NASDAQ:IMVT)

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

These Two Biotech Stocks Rocketed — And One Just Broke Out

Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN)

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow (NASDAQ:IMVT) 2026-04-02

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

스티펠, OmniAb에 ’매수’ 등급 재확인…파트너 성장 요인

Stifel reiterates Buy rating on OmniAb stock, cites partner growth